Overview

Safety Evaluation of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate for Refractory or Recurrent Metastatic Neuroblastoma Expressing Somatostatin Receptors

Status:
Not yet recruiting

Trial end date:
2022-04-01

Target enrollment:

Participant gender:

Summary

This multicentric, prospective study aime to determine the Maximum Tolerated Dose (MTD) of 2 intravenous injections of 177Lu-DOTA0-Tyr3-Octreotate (177Lu-DOTATATE) administered at 6 weeks apart in children with metastatic progressive neuroblastoma. The duration of study participation of each patient will be 3 months.

Phase:

Phase 1

Details

Lead Sponsor:

Institut Claudius Regaud

Treatments:

Lutetium Lu 177 dotatate
Octreotide
Somatostatin